We identified COL10A1 as a marker of high-risk BCC subtypes, particularly in sclerosing/infiltrative and basosquamous subtypes. This could serve as a prognostic biomarker and a target for personalized treatment.
This study investigates the use of cfDNA sequencing to monitor tumor dynamics in patients undergoing high-dose radiotherapy, revealing correlations between genetic alterations and clinical outcomes.
We developed machine learning models, PRIDICT2.0 and ePRIDICT, to predict prime editing efficiency, offering a robust tool for optimizing genome editing strategies across diverse chromatin contexts.
Method development for the analysis of cell-free DNA (cfDNA) sequencing data is impeded by limited data sharing due to the strict control of sensitive genomic data. An existing solution for facilitating data sharing removes nucleotide-level …
We investigated Talimogene laherparepvec (T-VEC) and its effect on the clinical, histological, single-cell transcriptomic and immune repertoire level using repeated fine-needle aspirates (FNAs) of injected and noninjected lesions in primary cutaneous B-cell lymphoma (pCBCL).
We are currently looking for Master’s students in the fields of Bioinformatics and Genomic Data Science for the topic of
Liquid biopsy-based cancer monitoring Cell-free DNA (cfDNA) is released by cells into the bloodstream or other bodily fluids. This cfDNA can easily be sampled through non-invasive methods called liquid biopsy. Like regular tissue biopsies, liquid biopsies also provide detailed genomic and epigenomic information about the tumor. Our research group focuses on identifying actionable biomarkers in cancer, that can be traced via blood tests and thus enable precision medicine.